Who is sponsoring NCT01241864?

NCT01241864 is sponsored by University of Chicago.

What condition does NCT01241864 study?

NCT01241864 studies Diabetes Mellitus, Type 1.

What drugs are being tested in NCT01241864?

Interventions: Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells.

What is the status of NCT01241864?

NCT01241864 is currently RECRUITING.

Last reviewed 2025-12-02 · How we verify

Islet Transplantation in Type 1 Diabetic Kidney Allograft

NCT01241864 Phase 2 RECRUITING

The purpose of this study is to learn about the safety of islet transplantation when performed after kidney transplantation, which may provide more normal control of blood sugar without the need for insulin shots. Islets are special clusters of cells within the pancreas that produce insulin. These cells will be obtained from cadaver (non-living) donors and given to subjects by vein.

Details

Lead sponsor	University of Chicago
Phase	Phase 2
Status	RECRUITING
Enrolment	10
Start date	2010-12
Completion	2026-12

Conditions

Diabetes Mellitus, Type 1

Interventions

Allogenic islet cells (human, U. Chicago)
Intraportal infusion of islet cells

Primary outcomes

HbAlc <6.5% and an absence of severe hypoglycemic events — 1 year after transplantation
The proportion of subjects with both an HbAlc \<6.5% and an absence of severe hypoglycemic events at 1 year after the first islet transplant or a reduction in HbAlc of at least 1 point and an absence of severe hypoglycemic events at 1 year after the first islet transplant.

Countries

United States